639 related articles for article (PubMed ID: 23640975)
1. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
Herzog A; Bian Y; Vander Broek R; Hall B; Coupar J; Cheng H; Sowers AL; Cook JD; Mitchell JB; Chen Z; Kulkarni AB; Van Waes C
Clin Cancer Res; 2013 Jul; 19(14):3808-19. PubMed ID: 23640975
[TBL] [Abstract][Full Text] [Related]
2. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
3. Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.
Leiker AJ; DeGraff W; Choudhuri R; Sowers AL; Thetford A; Cook JA; Van Waes C; Mitchell JB
Clin Cancer Res; 2015 Jun; 21(12):2792-801. PubMed ID: 25724523
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of the dual PI3K/MTOR inhibitor, PF-04691502, in combination with radiation in head and neck cancer.
Tonlaar N; Galoforo S; Thibodeau BJ; Ahmed S; Wilson TG; Yumpo Cardenas P; Marples B; Wilson GD
Radiother Oncol; 2017 Sep; 124(3):504-512. PubMed ID: 28823407
[TBL] [Abstract][Full Text] [Related]
5. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.
Yuan J; Mehta PP; Yin MJ; Sun S; Zou A; Chen J; Rafidi K; Feng Z; Nickel J; Engebretsen J; Hallin J; Blasina A; Zhang E; Nguyen L; Sun M; Vogt PK; McHarg A; Cheng H; Christensen JG; Kan JL; Bagrodia S
Mol Cancer Ther; 2011 Nov; 10(11):2189-99. PubMed ID: 21750219
[TBL] [Abstract][Full Text] [Related]
6. Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.
Fang DD; Zhang CC; Gu Y; Jani JP; Cao J; Tsaparikos K; Yuan J; Thiel M; Jackson-Fisher A; Zong Q; Lappin PB; Hayashi T; Schwab RB; Wong A; John-Baptiste A; Bagrodia S; Los G; Bender S; Christensen J; Vanarsdale T
PLoS One; 2013; 8(6):e67258. PubMed ID: 23826249
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.
Kashiyama T; Oda K; Ikeda Y; Shiose Y; Hirota Y; Inaba K; Makii C; Kurikawa R; Miyasaka A; Koso T; Fukuda T; Tanikawa M; Shoji K; Sone K; Arimoto T; Wada-Hiraike O; Kawana K; Nakagawa S; Matsuda K; McCormick F; Aburatani H; Yano T; Osuga Y; Fujii T
PLoS One; 2014; 9(2):e87220. PubMed ID: 24504419
[TBL] [Abstract][Full Text] [Related]
8. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
[TBL] [Abstract][Full Text] [Related]
9. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.
Sun ZJ; Zhang L; Hall B; Bian Y; Gutkind JS; Kulkarni AB
Clin Cancer Res; 2012 Oct; 18(19):5304-13. PubMed ID: 22859719
[TBL] [Abstract][Full Text] [Related]
10. PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.
Wander SA; Zhao D; Besser AH; Hong F; Wei J; Ince TA; Milikowski C; Bishopric NH; Minn AJ; Creighton CJ; Slingerland JM
Breast Cancer Res Treat; 2013 Apr; 138(2):369-81. PubMed ID: 23430223
[TBL] [Abstract][Full Text] [Related]
11. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C
Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792
[TBL] [Abstract][Full Text] [Related]
12. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma.
Wong CH; Loong HH; Hui CW; Lau CP; Hui EP; Ma BB; Chan AT
Invest New Drugs; 2013 Dec; 31(6):1399-408. PubMed ID: 23975511
[TBL] [Abstract][Full Text] [Related]
14. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y
PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154
[TBL] [Abstract][Full Text] [Related]
15. Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.
Madera D; Vitale-Cross L; Martin D; Schneider A; Molinolo AA; Gangane N; Carey TE; McHugh JB; Komarck CM; Walline HM; William WN; Seethala RR; Ferris RL; Gutkind JS
Cancer Prev Res (Phila); 2015 Mar; 8(3):197-207. PubMed ID: 25681087
[TBL] [Abstract][Full Text] [Related]
16. Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma.
Chou MH; Chuang HC; Lin YT; Tsai MH; Kao YH; Lin IC; Huang TL; Fang FM; Chien CY
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802643
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models.
Langdon SP; Kay C; Um IH; Dodds M; Muir M; Sellar G; Kan J; Gourley C; Harrison DJ
Sci Rep; 2019 Dec; 9(1):18742. PubMed ID: 31822716
[TBL] [Abstract][Full Text] [Related]
18. MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer.
Bian Y; Han J; Kannabiran V; Mohan S; Cheng H; Friedman J; Zhang L; VanWaes C; Chen Z
Int J Biol Sci; 2015; 11(4):411-22. PubMed ID: 25798061
[TBL] [Abstract][Full Text] [Related]
19. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
Marquard FE; Jücker M
Biochem Pharmacol; 2020 Feb; 172():113729. PubMed ID: 31785230
[TBL] [Abstract][Full Text] [Related]
20. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.
D'Amato V; Rosa R; D'Amato C; Formisano L; Marciano R; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fusciello C; Veneziani BM; De Placido S; Bianco R
Br J Cancer; 2014 Jun; 110(12):2887-95. PubMed ID: 24823695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]